Learning Objectives
- Demonstrate an increase in your knowledge of clinical medicine.
- Evaluate the appropriateness of clinical information as it applies to the care of your patients.
- Demonstrate an improvement in your ability to make decisions that provide safe and effective medical care.
- Recognize areas of personal strength and areas for growth in clinical knowledge.
Intended Audience
Physicians and residents who are seeking to maintain and augment their knowledge in pediatric medicine and/or who are preparing for their initial board certification or recertification.
Accreditation
The Massachusetts Medical Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement
The Massachusetts Medical Society designates this enduring material for a maximum of 153 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ABP MOC Statement
Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 153 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.
Royal College of Physicians and Surgeons of Canada
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Method of Participation
You must answer questions correctly to receive AMA PRA Category 1 Credits™ and ABP MOC points toward Certification Maintenance.
Six questions answered correctly are designated for 1 AMA PRA Category 1 Credit™ and 1 ABP MOC point.
CME Accreditation Term
Original Release Date: February 1, 2017
Review Date: 2018, 2019, 2020, 2021, 2022
Termination Date: February 1, 2024
Individual Disclosures
Below are all relevant financial relationships reported by NEJM Knowledge+ contributors during the past 3 years.
Vaneeta Bamba, MD
| 2020 | Nothing disclosed |
| 2021 | Novo Nordisk, Growth Advisory Board for Genetic Short Stature, discontinued Nov 2020 |
| 2022 | Nothing disclosed |
Ethan Brown, MD
| 2020 | Gateway Institute for Brain Research, grant/contract research Rune Labs, consultant, discontinued Apr 2019 |
| 2021 | Rune Labs, consultant, discontinued Apr 2019 |
| 2022 | Rune Labs, consultant |
Ezra M. Cohen, MD
| 2020 | Nothing disclosed |
| 2021 | Cornerstone Research Group, consultant |
| 2022 | Nothing disclosed |
Nathan Connell, MD
| 2020 | Nothing disclosed |
| 2021 | Nothing disclosed |
| 2022 | Takeda Pharmaceutical, consultant |
Rajesh T. Gandhi, MD
| 2020 | Merck, scientific advisory board |
| 2021 | Merck, scientific advisory board |
| 2022 | Nothing disclosed |
Jonathan S. Hausmann, MD
| 2020 | Novartis, consultant and advisory board member |
| 2021 | Pfizer, consultant, discontinued Dec 2020 Biogen, consultant, discontinued Dec 2020 Novartis, consultant |
| 2022 | Pfizer, consultant, discontinued Dec 2020 Biogen, consultant, discontinued Dec 2020 Novartis, consultant |
Brian C. Healy, MD
| 2020 | Analysis Group, grant funding Celgene, grant funding Novartis, grant funding Merck Serono, grant funding Verily Life Sciences, grant funding Tiziana, grant funding Genzyme, grant funding |
| 2021 | Analysis Group, grant support Celgene (Bristol–Myers Squibb), grant support Verily, grant support Novartis, grant support Merck Serono, grant support Genzyme, grant support |
| 2022 | Analysis Group, research support to institution, discontinued Nov 2020 Celgene (Bristol–Myers Squibb), research support to institution, discontinued Nov 2020 Novartis, research support |
Mihir M. Kamdar, MD
| 2020 | Amorsa Therapeutics, scientific advisory board Medtronic, consultant |
| 2021 | Amorsa Therapeutics, scientific advisory board, stockholder Medtronic, consultant, fees Fern Health, consultant, fees |
| 2022 | Nothing disclosed |
Ruslan Korets, MD
| 2020 | Nothing disclosed |
| 2021 | Boston Scientific, consultant |
| 2022 | Boston Scientific, consultant |
Jenna C. Lester, MD
| 2020 | Rodan + Fields, consultant |
Leigh C. Reardon, MD
| 2020 | Nothing disclosed |
| 2021 | Janssen, speaker CareDx, participant in advisory board discussion, discontinued Dec 2020 |
| 2022 | Janssen, advisory committee |
Derrick J. Todd, MD, PhD
| 2020 | Optum, consultant |
Ruth Ann Vleugels, MD, MPH, MBA
| 2021 | Pfizer, principal investigator for a clinical trial |
Raymond Y. Wang, MD
| 2020 | Biomarin Pharmaceuticals, advisory board / consultation, equity ownership RegenxBio, advisory board / consultation, equity ownership Takeda Pharmaceutical, advisory board / consultation Orphazyme, advisory board / consultation Inventiva Pharmaceutical, advisory board / consultation Sarepta Therapeutics, equity ownership |
| 2021 | Biomarin Pharmaceutical, speaking engagement, discontinued Jul 2019 Biomarin Pharmaceutical, advisory committee, discontinued Sep 2019 RegenxBio, advisory committee, discontinued May 2020 Takeda Pharmaceutical, advisory committee, discontinued Aug 2020 Ultragenyx Pharmaceutical, webinar, discontinued Nov 2020 Inventiva Pharmaceutical, advisory committee, discontinued Dec 2020 Neurogene, advisory committee, discontinued Nov 2020 Denali Therapeutics, drug monitoring committee |
| 2022 | Biomarin, ad hoc advisory board, discontinued Oct 2021 Orphazyme, ad hoc FDA advisory meeting, discontinued Oct 2021 Sio Gene Therapies, consultant, discontinued Nov 2021 Sio Gene Therapies, ad hoc advisory board, discontinued Aug 2021 Inventiva Pharmaceutical, ad hoc advisory board, discontinued Jul 2021 Takeda Pharmaceutical, ad hoc advisory board, discontinued Mar 2021 Ultragenyx, speaker, discontinued Nov 2020 Neurogene, ad hoc advisory board, discontinued Oct 2020 Regenxbio, ad hoc advisory board, discontinued Apr 2020 |
Sharmeel K. Wasan, MD
| 2020 | Nothing disclosed |
| 2021 | Pfizer, grant support |
| 2022 | Nothing disclosed |
All relevant financial relationships have been mitigated prior to the beginning of this activity in accordance with ACCME and MMS policies. All other individuals in control of the content have reported no relevant financial relationships with ineligible companies for this activity. The complete list of contributors can be found here.
Disclosure of Commercial Support
No commercial support was received for this activity.
Medium or Combination of Media Used
This is an adaptive self-assessment tool designed to adjust to the learner’s strengths and areas for growth, and can be accessed from a desktop, laptop, tablet, or smartphone. Learners choose the subspecialty area and are presented with a sequence of questions. After each question is answered, the user is provided with the key learning point, detailed feedback that discusses the correct answer as well as each of the wrong answers, and citations to relevant articles.
Estimated Time to Complete the Educational Activity
One hour for every 6 questions answered correctly.
Bibliography
Each clinical vignette includes citations and references.
Hardware/Software Requirements
Windows
- Google Chrome 30+, Safari 5.0+, Internet Explorer 11.0+, Mozilla Firefox 10.0+, Microsoft Edge
Recommended: Google Chrome 39+, Safari 7+, Internet Explorer 11, or Firefox 32+ - Windows 7 (32-bit and 64-bit), Windows 8+. Windows 7+ is recommended.
- Minimum 1 GB of RAM but 2 GB or greater is recommended
- 2.33 GHz or faster x86-compatible processor, or Intel® Atom™ 1.6 GHz or faster processor for netbooks
- Display resolution: 1024 × 768 or better
Mac OS
- Google Chrome 14+, Safari 5.0+, Mozilla Firefox 12.0+
Recommended: Google Chrome 39+, Safari 7+, or Firefox 32+ - Mac OS X v10.6+
- Minimum 1 GB of RAM but 2 GB or greater is recommended
- Intel Core™ Duo 1.33GHz or faster processor
- Display resolution: 1024 × 768 or better
Mobile/Tablet
NEJM Knowledge+ apps are currently available for iOS and Android smartphones and tablets; Android phones may access NEJM Knowledge+ through our mobile-optimized browser version. Please note that on September 29, 2022, NEJM Knowledge+ will be migrating to a new platform and are retiring both the iOS and Android apps. The new platform will work on all mobile and desktop systems via your web browser whenever you have an internet connection.
- iOS devices running OS 7+(includes iPhone and iPad devices). iOS version 8+ is recommended.
- Android version 4+ (includes smartphones and tablets). Android version 5+ is recommended. Note: Android phones will also support the browser version of each product (Chrome recommended).
Contact Information
For all questions and comments, please contact NEJM Knowledge+ by email at knowledgeplussupport@nejm.org or call toll-free +1-855-318-9303 (within the USA and Canada) or +1-781-434-7998.
Policy on Privacy and Confidentiality
Read our Privacy Policy.
Copyright
Copyright information can be found in the NEJM Group Terms of Use.